论文部分内容阅读
目的探讨多肿瘤标志物蛋白芯片在以占位病变为首发表现的良恶性鉴别价值。方法多肿瘤标志物蛋白芯片技术,检测以占位病变为首发表现的初诊病例血清中12项肿瘤标志物,并与病理结果进行对比分析。结果癌性病变与良性病变比较,甲胎蛋白(AFP)、铁蛋白(SF)、癌胚抗原(CEA)、糖类抗原CA125、CA153和CA199等的血清水平升高,且AFP、CEA和CA125的阳性率也明显升高;癌性病变中,仅男性患者SF血清水平和阳性率较肉瘤病变显著升高;肉瘤病变中,仅女性患者SF血清水平和阳性率较良性病变显著升高。结论多肿瘤标志物蛋白芯片对以占位病变为首发表现的良恶性病变有鉴别意义。
Objective To investigate the differential value of multiple tumor marker protein chip in the first manifestation of mass lesions. Methods Multi-tumor marker protein chip technology was used to detect 12 tumor markers in newly diagnosed cases with mass lesions as the first manifestation, and compared with the pathological results. Results The serum levels of AFP, SF, CEA, carbohydrate antigens CA125, CA153 and CA199 were higher in cancerous lesions than in benign lesions, and the levels of AFP, CEA and CA125 The positive rate of SF in cancer patients was significantly higher than that of sarcomas in only male patients. In the sarcoma lesions, the serum level and positive rate of SF in female patients were significantly higher than those in benign lesions. Conclusions Multi-tumor marker protein chips are of differential significance for the benign and malignant lesions with occupying lesions as the first manifestation.